The Future of Cardiac Molecular Imaging.


Journal

Seminars in nuclear medicine
ISSN: 1558-4623
Titre abrégé: Semin Nucl Med
Pays: United States
ID NLM: 1264464

Informations de publication

Date de publication:
Jul 2020
Historique:
entrez: 17 6 2020
pubmed: 17 6 2020
medline: 6 7 2021
Statut: ppublish

Résumé

Molecular imaging with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) serves numerous applications in clinical cardiology and research. Similar to other medical imaging technologies, this area has undergone and continues to experience rapid changes resulting from technological and medical advances. These have immediate impacts on diagnosis, treatment planning, and patient care, as well as supplying innovative tools for fundamental and translational research. A broad shift toward hybrid PET systems and incorporation of advanced computational tools has been accompanied by mechanism-specific, targeted radiopharmaceuticals that seek to address long-standing limitations in cardiac imaging. While this review addresses some of the still-emerging clinical uses of established radiopharmaceuticals, it too highlights newer imaging probes, applications, and imaging techniques and instrumentation on the horizon. We highlight molecular imaging advances in inflammatory and infiltrative myocardial conditions, heart metabolism, vascular and valvular diseases, neurohormonal dysregulation, and transformational technical advances such as the rise of artificial intelligence and theranostic approaches to cardiovascular disease.

Identifiants

pubmed: 32540033
pii: S0001-2998(20)30006-4
doi: 10.1053/j.semnuclmed.2020.02.005
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

367-385

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Gedaliah Farber (G)

University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, ON, Canada.

Kevin E Boczar (KE)

University of Ottawa Heart Institute, Ottawa, ON, Canada.

Christiane C Wiefels (CC)

University of Ottawa Heart Institute, Ottawa, ON, Canada.

Jason G E Zelt (JGE)

University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.

Emel Celiker Guler (EC)

University of Ottawa Heart Institute, Ottawa, ON, Canada.

Robert A deKemp (RA)

University of Ottawa Heart Institute, Ottawa, ON, Canada.

Rob S Beanlands (RS)

University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.

Benjamin H Rotstein (BH)

University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, ON, Canada. Electronic address: benjamin.rotstein@uottawa.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH